Next, we will continue to improve cell experiments to further demonstrate the expression and function of NUCB1 in colorectal cancer cells, and explore whether the combination of NUCB1 and COX-2 induces bevacizumab resistance. This evidence concerns the gene NUCB1 and colorectal cancer.